Patents for A61P 35 - Antineoplastic agents (221,099)
01/2001
01/11/2001WO2001002377A1 Telomerase inhibitors and methods of their use
01/11/2001WO2001002369A2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
01/11/2001WO2001002349A1 Phenyl sulfamate derivatives
01/11/2001WO2001002019A2 Control of gene expression
01/11/2001WO2001002018A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them
01/11/2001WO2001002017A2 Erythropoietin conjugates with polyethylenglycol
01/11/2001WO2001001988A1 Compounds having cytokine inhibitory activity
01/11/2001WO2001001981A1 Vegf receptor antagonists
01/11/2001WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy
01/11/2001WO2001001922A2 Use of substance p antagonists for the treatment of adenocarcinoma
01/11/2001WO2001001890A1 Stent coating
01/11/2001WO2001001748A2 Peptide compounds that bind her2
01/11/2001WO2000066604A3 L-ribo-lna analogues
01/11/2001WO2000063364A3 Methods and compositions for inhibiting the function of polynucleotide sequences
01/11/2001WO2000062800A3 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
01/11/2001WO2000062657A3 Improvement of t cell mediated immunity
01/11/2001WO2000061546A3 Novel aryl-chloro-ethyl ureas
01/11/2001WO2000061543A3 Esters of l-carnitine or alkanoyl l-carnitines
01/11/2001WO2000061189A3 Water-soluble compositions of bioactive lipophilic compounds
01/11/2001WO2000061167A3 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
01/11/2001WO2000059515A3 Immunomodulating polymers
01/11/2001WO2000059485A3 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
01/11/2001WO2000058466A3 Protease resistant flint analogs
01/11/2001WO2000056351A3 Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
01/11/2001WO2000054770A8 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
01/11/2001WO2000053748A3 Casb618 polynucleotides and polypeptides and their use
01/11/2001WO2000053216A3 Use of casb616 polypeptides and polynucleotides for cancer treatment
01/11/2001WO2000053169A8 Method of inhibiting a chaperone protein
01/11/2001WO2000048581A3 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
01/11/2001WO2000047622A3 Peptides with anti-angiogenic activity
01/11/2001WO2000046251A3 Human polyclonal antibodies from transgenic nonhuman animals
01/11/2001WO2000029551B1 Cells, culture methods, and their use in autologous transplantation therapy
01/11/2001WO2000029012A8 Methods of alleviating cancer symptoms
01/11/2001DE19932315A1 Benzoylpyridazine Benzoylpyridazine
01/11/2001DE19930177A1 Intermolekular assoziierende Verbindungen und diese umfassende Aggregate Inter-molecular compounds and associating this comprehensive aggregates
01/11/2001DE19929887A1 cDNA-Sequenzen von zwei Interakoren FANCIP2 und FANCIP3 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequences of two Interakoren FANCIP2 and FANCIP3 of the Fanconi anemia complementation group A-protein of the
01/11/2001CA2380875A1 Cell death related drug targets in yeast and fungi
01/11/2001CA2378324A1 Recombinant adenovirus
01/11/2001CA2378116A1 Human immune response molecules
01/11/2001CA2377795A1 Use of the krit1 gene in angiogenesis
01/11/2001CA2377788A1 Methods for modulating angiogenesis by using the anti-angiogenic angiotensin-7 and polynucleotides encoding therefor
01/11/2001CA2377731A1 Fusion peptides comprising a peptide ligand domain and a multimerization domain
01/11/2001CA2377381A1 Neovascular-targeted immunoconjugates
01/11/2001CA2376681A1 Novel xanthone compounds, their preparation and use as medicament
01/11/2001CA2376657A1 Indole derivatives and their use for the treatment of osteoporosis amongst other applications
01/11/2001CA2376513A1 An interleukin-1 receptor antagonist and uses thereof
01/11/2001CA2376166A1 Control of gene expression
01/11/2001CA2375091A1 Crystals of benzimidazole compounds
01/11/2001CA2373960A1 Use of substance p antagonists for the treatment of adenocarcinoma
01/11/2001CA2373882A1 Compounds having cytokine inhibitory activity
01/11/2001CA2373352A1 Adenoviral vectors for treating disease
01/11/2001CA2341253A1 Telomerase inhibitors and methods of their use
01/10/2001EP1066833A2 Cryopreserved cells, system for supplying cells on commission, and preventive or remedial method of infections or cancers
01/10/2001EP1066830A2 Uses and compositions for treating primary and secondary tumors of the central nervous system (cns)
01/10/2001EP1066378A2 Lyst protein complexes and lyst interacting proteins
01/10/2001EP1066377A1 Methods for prevention and treatment of cancer
01/10/2001EP1066370A1 Stimulated monocyte derived cells, their preparation and uses
01/10/2001EP1066321A2 Formulation having a papilloma virus-specific protein, and the production and use thereof
01/10/2001EP1066311A1 Compositions and methods for the identification of lung tumor cells
01/10/2001EP1066304A1 Macrolide lhrh antagonists
01/10/2001EP1066297A1 Phosphinic acid derivatives
01/10/2001EP1066293A2 New porphyrins and their use
01/10/2001EP1066286A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
01/10/2001EP1066285A1 Antagonists of gonadotropin releasing hormone
01/10/2001EP1066280A1 Halimide, a cytotoxic marine natural product, and derivatives thereof
01/10/2001EP1066273A1 Metalloproteinase inhibitors
01/10/2001EP1066268A1 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists
01/10/2001EP1066266A1 Cyclin dependent kinase inhibitors
01/10/2001EP1066257A2 Heterocylic classes of compounds for the modulating tyrosine protein kinase
01/10/2001EP1066221A2 Vectors and viruses used in gene therapy
01/10/2001EP1066059A1 Formulations for protection of peg-interferon alpha conjugates
01/10/2001EP1066050A2 Application of hsp70 proteins
01/10/2001EP1066034A1 Oxy-vanadium (iv) complexes having spermicidal activity
01/10/2001EP0977592A4 Method for improved selectivity in photo-activation of molecular agents
01/10/2001EP0796103B1 Use of incense in the treatment of alzheimer's disease
01/10/2001CN1279692A Anti-idiotype monoclonal antibodise, their use in active immunotherapy of malignant tumors and compositions containing them
01/10/2001CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
01/10/2001CN1279687A Bi-and tri-cyclic nucleoside, nucleotide and oligonucleotide analoguse
01/10/2001CN1279680A Imidazole derivatives with inhabiting activity to transterasa and preparing method thereof
01/10/2001CN1279677A Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
01/10/2001CN1279669A Aromatic sulfone hydroxamic acid metalloprotease inhibitor
01/10/2001CN1279666A NPY antagonists
01/10/2001CN1279616A Synergistic composition and methods for treating neoplanstic or cancerous growths and for restoring or boosting hematopoiesis
01/10/2001CN1279239A Acridine carboxylic ester compound, preparation and medicinal composition thereof
01/10/2001CN1279236A Salt as thrombin inhibitor
01/10/2001CN1279107A Medicine for treating AIDS and tumor and its preparing process
01/10/2001CN1279077A Concentrated pill for treating tumor
01/10/2001CN1279073A Antisenility Chinese medicine
01/10/2001CN1060472C Hydroxamic acid derivatives with tricylic substitution, their preparing methods, medicines containing them and uses thereof
01/10/2001CN1060391C Traditional Chinese medicine for treating gynecological tumour
01/10/2001CN1060383C Pills for cancers
01/10/2001CN1060357C Pellet with immunity detoxication function and preparation method
01/09/2001US6172261 Biosynthesis using chain extension
01/09/2001US6172256 Chiral-β-amino acid compounds and derivatives thereof
01/09/2001US6172250 Hydrolysis of an organosilicon compounds
01/09/2001US6172239 Psychological, nervous system disorders
01/09/2001US6172211 Nucleotide sequences which codes a protein that modulates tumor propagation; for the treatment of cancer; antitumor agents; anticarcinogenic agents; antiproliferative agents
01/09/2001US6172201 Cellular receptor for HIV-1 Vpr essential for G2/M phase
01/09/2001US6172194 ARF-p19, a novel regulator of the mammalian cell cycle
01/09/2001US6172116 Use of aminoadamantane compounds as immunoregulators